Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Inclusion Criteria:

   - Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC

   - Unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm
   N2 or N3 disease; patients may have invasive mediastinal staging by mediastinoscopy,
   mediastinotomy, endobronchial ultrasound transbronchial aspiration (EBUS-TBNA),
   endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery (VATS)

   - Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3
   disease are eligible if deemed unresectable; patients with T4, any N are eligible

   - Patients must have measurable disease, i.e., lesions that can be accurately measured
   in at least 1 dimension (longest dimension in the plane of measurement is to be
   recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan slice
   thickness no greater than 5 mm)

   - Patients with a pleural effusion, which is a transudate, cytologically negative and
   non-bloody, are eligible if the radiation oncologist feels the tumor can be
   encompassed within a reasonable field of radiotherapy

   - If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too
   small to tap, the patient will be eligible; patients who develop a new pleural
   effusion after thoracotomy or other invasive thoracic procedure will be eligible

   - The institution's pre-enrollment biomarker screening at a Clinical Laboratory
   Improvement Amendments (CLIA) certified lab documents presence of known "sensitive"
   mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon
   19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement;
   either the primary tumor or the metastatic lymph node tissue may be used for testing
   of mutations

   - The institution's pre-enrollment biomarker screening at a CLIA certified lab documents
   absence of T790M mutation in the EGFR TK domain

   - Appropriate stage for protocol entry, including no distant metastases, based upon the
   following minimum diagnostic workup:

      - History/physical examination, including recording of pulse, blood pressure (BP),
      weight, and body surface area, within 45 days prior to registration

      - Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to
      mid-thighs) within 30 days prior to registration; PET/CT must be negative for
      distant metastasis

      - CT scan with contrast of the chest and upper abdomen to include liver and
      adrenals (unless medically contraindicated) within 30 days prior to registration

      - Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with
      contrast, if MRI medically contraindicated) within 30 days prior to registration

   - Zubrod performance status 0-1 within 14 days prior to registration

   - Absolute neutrophil count (ANC) >= 1,000 cells/mm^3

   - Platelets >= 100,000 cells/mm^3

   - Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve
   hemoglobin [Hgb] >= 8.0 g/dl is acceptable)

   - Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 ml/min (by
   Cockcroft-Gault formula) within 14 days prior to registration

   - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit
   of normal (ULN) within 14 days prior to registration

   - Bilirubin within normal institutional limits within 14 days prior to registration

   - Negative serum pregnancy test within 14 days prior to registration for women of
   childbearing potential

   - Patient must provide study specific informed consent prior to study entry, including
   consent for mandatory screening of tissue

Exclusion Criteria:

   - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
   for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast,
   oral cavity, or cervix are all permissible)

   - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
   different cancer is allowable

   - Prior radiotherapy to the region of the study cancer that would result in overlap of
   radiation therapy fields

   - Atelectasis of the entire lung

   - Contralateral hilar node involvement

   - Exudative, bloody, or cytologically malignant effusions

   - Severe, active co-morbidity, defined as follows:

      - Unstable angina and/or congestive heart failure requiring hospitalization within
      the last 6 months

      - Transmural myocardial infarction within the last 6 months

      - Acute bacterial or fungal infection requiring intravenous antibiotics at the time
      of registration

      - Chronic obstructive pulmonary disease exacerbation or other respiratory illness
      requiring hospitalization or precluding study therapy at the time of
      registration; hepatic insufficiency resulting in clinical jaundice and/or
      coagulation defects

      - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease
      Control and Prevention (CDC) definition; note, however, that human
      immunodeficiency virus (HIV) testing is not required for entry into this
      protocol; protocol-specific requirements may also exclude immuno-compromised
      patients

   - Pregnancy or women of childbearing potential and men who are sexually active and not
   willing/able to use medically acceptable forms of contraception

   - Prior allergic reaction to the study drug(s) involved in this protocol